Publications
69
Citations
1,092
Est. group size
~1
Recurring co-author estimate
Active years
57
Publishing since 1968
Jessica M. Brown's work focuses on cancer treatment, particularly combination drug therapies for urothelial (bladder-related) carcinoma, including studies on how chemotherapy and immunotherapy drugs work together to improve patient outcomes. Her research also touches on cancer survivorship topics, such as physical fitness testing protocols for cancer patients. This research is largely clinical, involving data from treatment trials and outcome assessments.
Publication output was relatively steady but modest from 2017-2023, with a sharp spike in 2024 driven largely by multiple linked outputs (data, tables, figures) from a single major study.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
Cancer Research Communications · 2024
- Data from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- TABLE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- Supplementary figure S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- FIGURE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- FIGURE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- Supplementary table S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- TABLE 1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- TABLE 4 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- TABLE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- TABLE 1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- FIGURE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- TABLE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- Data from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- FIGURE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
2024
- Medicine & Science in Sports & Exercise×17
- Translational Journal of the American College of Sports Medicine×2
- Journal of Clinical Exercise Physiology×2
- Academic Pediatrics×2
- Science Translational Medicine×1
- Marcy Haynam
Medicine · The Ohio State University
- Diane Von Ah
Medicine · The Ohio State University
- Ellen Krueger
Medicine · Indiana University
- Bruce A. Cooper
Medicine · Purdue University West Lafayette
- Michelle J. Naughton
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile